STEMI
151
17
23
66
Key Insights
Highlights
Success Rate
97% trial completion (above average)
Research Maturity
66 completed trials (44% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
1.3%
2 terminated out of 151 trials
97.1%
+10.6% vs benchmark
20%
30 trials in Phase 3/4
14%
9 of 66 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 66 completed trials
Clinical Trials (151)
Advancing Cardiac Care Unit-based Rapid Assessment and Treatment of hypErcholesterolemia
Analysis of the Microbiota and STEMI
Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock
Empagliflozin for No-reflow Phenomenon in PCI for STEMI
Delivery SSO2 Therapy for 60 Min in Anterior MI Patients With PCI ≤ 6 Hours of Symptoms Onset Compared to Standard.
Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI
AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS
The "MyoThrombus" Study
Antiplatelets and Intramyocardial Hemorrhage in STEMI: Incidence and Outcomes
Drug-Coated Balloon Primary PCI in ST-Segment Elevation Myocardial Infarction
Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus
The Coronary Sinus Balloon Pump in STEMI
A Study of Acute Myocardial Infarction Using FDY-5301
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
Impact of Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction
STaged Interventional Strategies for Acute ST-seGment Elevation Myocardial Infarction Patient With Multi-vessel Disease（STAGED）
TIRANA-ACS: A Prospective Registry Study for the Targeted Investigation of Residual Inflammation After Non-ST/ ST Elevation Acute Coronary Syndrome
Evaluation in STEMI Patients Using FDY-5301
Assessment of Individual Risk of Cardiovascular Events by Platelet FcGammaRIIa
Inflammatory and Hematological Indices in Diabetic STEMI Patients Undergoing Primary PCI